Pegfilgrastim
- Atc Codes:L03AA13
- CAS Codes:208265-92-3
- PHARMGKB ID:208265-92-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Neulasta; Belgium: Neulasta; Czech Republic: Neulasta; Denmark: Neulasta; Estonia: Neulasta; Finland: Neulasta; France: Neulasta; Germany: Neulasta; Greece: Neulasta; Hungary: Neulasta; Ireland: Neulasta; Italy: Neulasta; Latvia: Neulasta; Lithuania: Neulasta; Luxembourg: Neulasta; Malta: Neulasta; Netherlands: Neulasta; Poland: Neulasta; Portugal: Neulasta; Romania: Neulasta; Slovakia: Neulasta; Spain: Neulasta; Sweden: Neulasta; UK: Neulasta.
North America
Canada: Neulasta; USA: Neulasta.
Latin America
Argentina: Neulastim; Mexico: Neulastim.
Drug combinations
Chemistry
Pegfilgrastim: C~849~H~1347~N~223~O~244~S~9~ (C~2~H~4~O)~n~. N-(3-Hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with α-methyl-ω-hydroxypoly(oxyethylene). CAS-208265-92-3.
Pharmacologic Category
Hematopoietic Agents; Colony Stimulating Factor. (ATC-Code: L03AA13).
Mechanism of action
Stimulates production, maturation, and activation of neutrophils. Pegfilgrastim activates neutrophils to increase both migration and cytotoxicity.
Therapeutic use
To decrease incidence of infection, by stimulation of granulocyte production, in patients with nonmyeloid malignancies receiving myelosuppressive therapy associated with significant risk of febrile neutropenia.
Pregnancy and lactiation implications
Animal studies demonstrated adverse effects and fetal loss. There are no adequate, well-controlled studies in pregnant women. Use only if potential benefit to mother justifies potential risk to fetus. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to pegfilgrastim, filgrastim, E. coli-derived proteins, or any component of the formulation.
Warnings and precautions
Allergic reactions (anaphylaxis, skin rash, erythema, and urticaria) occurred. Acute respiratory distress syndrome reported. Rare cases of splenic rupture reported. May precipitate sickle cell crises in sickle cell disease. Pegfilgrastim should not be used in period 14 days before to 24 hours after administration of cytotoxic chemotherapy (potential sensitivity of rapidly-dividing myeloid cells to cytotoxic chemotherapy). 6 mg fixed dose should not be used in adolescents weighing <45 kg. Packaging (needle cover) contains latex. May potentially act as growth factor for any tumor type, particularly myeloid malignancies. Tumors of nonhematopoietic origin may have surface receptors for pegfilgrastim.